Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Novo Nordisk stock fell nearly 6% during Friday morning trading after it posted the results. The Danish pharma giant tested monlunabant, a drug it acquired in 2023 with its $1 billion purchase of ...

Operating profit increased by 21% in Danish kroner and by 22% at constant exchange rates (CER) to DKK 91.6 billion.Sales in ...

Earlier on Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist.

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...

However, recent efficacy and side effect concerns over Novo Nordisk's pipeline candidate Monlunabant have likely worsened NVO's recent buying sentiments as investors reassessed future growth ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Novo Nordisk remains the market leader in international ... And we're anticipating a Phase 2 readout for monlunabant in diabetes kidney disease in Q4. Lastly, within diabetes, we are awaiting ...

Novo Nordisk’s third-quarter sales growth was ... early data for a novel oral obesity drug candidate, CB1-targeting monlunabant. We had not yet included monlunabant explicitly in our model ...

Within R&D, Novo Nordisk completed the phase 2a trial with monlunabant in obesity and expects to initiate a larger phase 2b trial in obesity in 2025 to further investigate the dosing and safety ...